Literature DB >> 15296829

Rise and fall of minocycline in neuroprotection: need to promote publication of negative results.

Elsa Diguet1, Christian E Gross, François Tison, Erwan Bezard.   

Abstract

Initial studies conducted on the neuroprotective effects of minocycline, a second-generation tetracycline, in experimental models of neurodegeneration gave promising results. However, more recently, minocycline has clearly been shown to have variable and even contradictory (beneficial or detrimental) effects in different species and models of neurological disorders, and its "neuroprotective" mechanisms remain to be clarified. Although its anti-inflammatory properties are likely to contribute to its neuroprotective effects observed in several animal models, a body of recent evidence indicates that our community should proceed with caution in the clinical use of minocycline for central nervous system disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15296829     DOI: 10.1016/j.expneurol.2004.05.016

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  22 in total

1.  Fighting publication bias: introducing the Negative Results section.

Authors:  Ulrich Dirnagl; Martin Lauritzen
Journal:  J Cereb Blood Flow Metab       Date:  2010-07       Impact factor: 6.200

Review 2.  Bridge between neuroimmunity and traumatic brain injury.

Authors:  Matthew L Kelso; Howard E Gendelman
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  Melatonin and minocycline for combinatorial therapy to improve functional and histopathological deficits following traumatic brain injury.

Authors:  Matthew L Kelso; Nicole N Scheff; Stephen W Scheff; James R Pauly
Journal:  Neurosci Lett       Date:  2010-11-05       Impact factor: 3.046

4.  Minocycline confers early but transient protection in the immature brain following focal cerebral ischemia-reperfusion.

Authors:  Christine Fox; Andra Dingman; Nikita Derugin; Michael F Wendland; Catherine Manabat; Shaoquan Ji; Donna M Ferriero; Zinaida S Vexler
Journal:  J Cereb Blood Flow Metab       Date:  2005-09       Impact factor: 6.200

5.  Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess.

Authors:  Tammy Kielian; Nilufer Esen; Shuliang Liu; Nirmal K Phulwani; Mohsin M Syed; Napoleon Phillips; Koren Nishina; Ambrose L Cheung; Joseph D Schwartzman; Jorg J Ruhe
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

6.  Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.

Authors:  Liliana B Menalled; Monica Patry; Natalie Ragland; Phillip A S Lowden; Jennifer Goodman; Jennie Minnich; Benjamin Zahasky; Larry Park; Janet Leeds; David Howland; Ethan Signer; Allan J Tobin; Daniela Brunner
Journal:  PLoS One       Date:  2010-03-22       Impact factor: 3.240

7.  Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS.

Authors:  Eva-Maria Ratai; Jeffrey P Bombardier; Chan-Gyu Joo; Lakshmanan Annamalai; Tricia H Burdo; Jennifer Campbell; Robert Fell; Reza Hakimelahi; Julian He; Patrick Autissier; Margaret R Lentz; Elkan F Halpern; Eliezer Masliah; Kenneth C Williams; Susan V Westmoreland; R Gilberto González
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

Review 8.  Minocycline: far beyond an antibiotic.

Authors:  N Garrido-Mesa; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

9.  Minocycline attenuates microglial activation but fails to mitigate degeneration in inferior olive and pontine nuclei after focal cerebellar lesion.

Authors:  M T Viscomi; L Latini; F Florenzano; G Bernardi; M Molinari
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

10.  Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke.

Authors:  Noriyuki Matsukawa; Takao Yasuhara; Koichi Hara; Lin Xu; Mina Maki; Guolong Yu; Yuji Kaneko; Kosei Ojika; David C Hess; Cesar V Borlongan
Journal:  BMC Neurosci       Date:  2009-10-06       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.